SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) OCTOBER 19, 1995 ENZON,
INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
Enzon, Inc. ("Enzon" or the "Company") has been advised by Sanofi
Winthrop, Inc. that the Phase III clinical trial of DISMUTEC<trademark>
(pegorgotein) in patients with severe closed head injury has been evaluated
and fails to show a statistically significant difference between the
treatment group and the control group. DISMUTEC, the enzyme superoxide
dismutase modified with Enzon's proprietary PEG-technology, is designed to
decrease tissue injury caused by ischemia or trauma in severe closed head
injury patients. Through modification with Enzon's PEG-technology,
DISMUTEC exhibited longer circulating half-life and reduced immunogenicity;
however, the drug showed insufficient therapeutic effect for this
indication. The Company believes the results of the clinical trial have no
immediate impact on the Company from an earnings or cash flow perspective
and that these results do not reflect adversely on the Company's other
products or PEG-technology.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: October 20, 1995
ENZON, INC.
(Registrant)
By: /S/ KENNETH J. ZUERBLIS Kenneth J. Zuerblis
Vice President, Finance
(Principal Financial and
Accounting Officer)
